Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1.2BCash on Hand
75.1mo Cash Runway
Follow DNTH by emailGet an email when DNTH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about DNTH, unsubscribe in one click. Privacy
📣 What DNTH Says Is Next
in 2027 · “Following top-line results, a Phase 3 trial in MMN is planned to initiate in 2027.”
Company press release, Nov 4, 2026 · SEC filing
2H · “Q4W in gMG patients was initiated in June, with top-line results expected in 2H’28.”
Company press release, Nov 4, 2026 · SEC filing
2H · Claseprubart: “Phase 3 EMERGE trial on track with top-line results expected in 2H’28: A Phase 3 registrational trial of claseprubart evaluating 300mg/2mL S.C.”
Company press release, Nov 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 4, 2026 ·
Earnings Reported Q3 2026 results with about $1.2 billion in cash as of September 30, 2026, expected to fund operations into 2030. Phase 2 MoMeNtum trial of claseprubart in MMN is on track for top-line results in December 2026, and CAPTIVATE Part A showed a 75% response rate in an interim analysis of 40 participants. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 18, 2026 ·
Financing Dianthus Therapeutics filed a automatic shelf registration covering an indeterminate amount of common stock, preferred stock, debt securities, warrants and units. Form S-3ASR · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 2 · Active Trial · A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy Registry primary completion date, not a results date
Dec 2028 · Phase 3 · Recruiting · A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) Registry primary completion date, not a results date
Dec 2028 · Phase 3 · Recruiting · A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) Registry primary completion date, not a results date
Jul 2025 · Phase 2 · Active Trial · A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
DNTH holds $1.2B in cash and short-term investments (as of Sep 30, 2026) and burns about $49.7M/quarter from operations,
an estimated runway of 75.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:24 · Moderate
Cash runway 75 months
ATM program on file since Sep 2026 +15
Shelf registration (S-3ASR, Sep 2026) +10
Company says cash lasts into 2030 -15Based on our current operating plan, we believe that our existing cash, cash equivalents and investments as of September 30, 2026 should be sufficient to fund our operations into 2030.10-Q, Nov 2026
Share count +31% in a year +14
Recent financing filings on SEC EDGAR:
Sep 18, 2026 · Shelf registration with ATM program, up to $500M · S-3ASR
Share count 56,312,712 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full DNTH picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DNTH and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.